License Agreements (Details Textual)	1 Months Ended			3 Months Ended		6 Months Ended				3 Months Ended		6 Months Ended
	Apr. 30, 2012 USD ($)	Jun. 30, 2009 USD ($)	Jun. 30, 2009 EUR (€)	Jun. 30, 2012 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2012 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2012 EUR (€)	Apr. 03, 2012 USD ($)	Jun. 30, 2012 Lohmann Therapie Systeme [Member] USD ($)	Mar. 31, 2011 Lohmann Therapie Systeme [Member] USD ($)	Jun. 30, 2012 Lohmann Therapie Systeme [Member] USD ($)	Jun. 30, 2011 Lohmann Therapie Systeme [Member] USD ($)
Commercial Supply License Agreements [Line Items]
Royalty expense				$ 4,000	$ 3,000	$ 9,000	$ 6,000			$ 13,000	$ 9,000	$ 28,000	$ 19,000
License Agreements (Textual) [Abstract]
Development and the commercialization rights granted		41,800,000	30,000,000
Future milestone payments			65,000,000
Upfront payment future development expenses		7,000,000	5,000,000
Option payments								5,000,000
Collaboration revenue				1,800,000	1,800,000	3,600,000	3,600,000
Deferred revenue				28,700,000		28,700,000
Deferred revenue current for license agreements				7,200,000		7,200,000
Product supply transactions					100,000		600,000
Royalties on net sales						1,000,000
Royalty Revenue				400,000	200,000	700,000	400,000
Settlement agreement						(i) an initial cash payment of $300,000, (ii) potential additional cash payments of up to an individual aggregate of $450,000 in the event the Company achieves certain annual sales milestones for Qutenza and (iii) certain royalties on net sales of products utilizing intellectual property licensed by the Company under the U.C. License Agreement. Additionally, pursuant to the terms of the Settlement Agreement, these individuals have each been granted, pursuant to the terms of the Company’s 2007 Stock Plan, as amended, a restricted stock purchase award for 75,000 shares of common stock of the Company that they may elect to purchase within five years of the date of the Agreement. The purchase price for such shares was set at $0.3904 per share.
Initial cash payment	300,000
Additional cash payments of up to an individual	450,000
Restricted stock purchase									75,000
Purchase price of shares									$ 0.3904
Right to offset of cash and royalty payments	50.00%
Deferred product revenue				$ 11,000		$ 11,000